PIRAMAL ENTERPRISES LTD. - 500302 - Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s
Intimation under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Appointment of Statutory Auditors PIRAMAL ENTERPRISES LTD. - 500302 - Announcement under Regulation 30 (LODR)-Change in Directorate
Intimation under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Appointment of Independent Director PIRAMAL ENTERPRISES LTD. - 500302 - Board Meeting Outcome for Outcome Of Board Meeting Held Today: 1. Audited Financial Results (Standalone And Consolidated) For The Quarter / Year Ended 31St March, 2022; 2. Dividend; 3. Record Date; 4. Annual General Meeting
Outcome of Board Meeting held today: 1. Audited Financial Results (Standalone and Consolidated) for the quarter / year ended 31st March, 2022; 2. Dividend; 3. Record Date; 4. Annual General Meeting Q4FY22 Quarterly Result Announced for Piramal Enterprises Ltd.
Finance company Piramal Enterprises announced Q4FY22 results: FY22 revenues at Rs 13,993 crore; FY22 Net Profit at Rs 1,999 crore Q4 FY22 Net Profit of Rs 151 crore vs Loss of Rs. 510 crore in Q4 FY21 The Board has recommended a dividend of Rs 33 per share, subject to shareholders’ approval FS business Pre-provision Operating Profit (PPOP) of Rs 379 crore in Q4 FY22 vs. Rs 243 crore in Q4 FY21 Overall AUM grew +33% YoY to Rs 65,185 crore; retail loan book grew 306% YoY to Rs 21,552 crore DHFL acquisition completed with most branches integrated and re-activated Pharma business revenues grew 16% YoY to Rs 6,701 Cr for FY22 India Consumer Healthcare grew 48% YoY and Complex Hospital Generics business grew 20% YoY during FY22 EBITDA margin for the Pharma business stood at 18% during FY22 Expect to complete the demerger in Q3 FY23, subject to various required approvals Ajay Piramal, Chairman, Piramal Enterprises Ltd. said, “We have delivered a resilient performance in Q4 and FY22 across financial services and pharmaceuticals, against the backdrop of the pandemic and macro-economic headwinds. In financial services, we completed the integration with DHFL and achieved 100% Q-on-Q growth in retail loan disbursements in Q4 of FY22. We have re-activated almost all the branches and not only retained over 3,000 employees of the DHFL, but also created over 3,000 new jobs in the merged entity across India. We will continue to make requisite investments in talent and technology, to strengthen our ability to tap the latent business opportunities in the Bharat market. Post the DHFL acquisition, we will now leverage our sizable retail lending platform to double our AUM over the next 5 years, thereby significantly improving our mix towards retail. During the quarter, we further strengthened our balance sheet by making additional provisions towards Stage 2 assets. We also continue to retain the extraordinary provisions made in March 2020 towards the pandemic related risks In pharmaceuticals, we have been investing organically and inorganically across all our businesses. All our key businesses have a compelling plan for their growth and have continued to deliver against their respective strategic priorities despite challenging macro-environment. We remain firmly on track to complete the demerger of the pharmaceuticals business by Q3 of FY23 and unlock significant value for our stakeholders." Result PDF PIRAMAL ENTERPRISES LTD. - 500302 - Corporate Action-Board approves Dividend
Outcome of Board Meeting held today: 1. Audited Financial Results (Standalone and Consolidated) for the quarter / year ended 31st March, 2022; 2. Dividend; 3. Record Date; 4. Annual General Meeting PIRAMAL ENTERPRISES LTD. - 500302 - Outcome Of Board Meeting Held Today: 1. Audited Financial Results (Standalone And Consolidated) For The Quarter / Year Ended 31St March, 2022; 2. Dividend; 3. Record Date; 4. Annual General Meeting
Outcome of Board Meeting held today: 1. Audited Financial Results (Standalone and Consolidated) for the quarter / year ended 31st March, 2022; 2. Dividend; 3. Record Date; 4. Annual General Meeting PIRAMAL ENTERPRISES LTD. - 500302 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 PIRAMAL ENTERPRISES LTD. - 500302 - Announcement under Regulation 30 (LODR)-Allotment
Intimation with respect to allotment of Secured, Rated, Listed, Redeemable Principal Protected, Market Linked Non-Convertible Debentures PIRAMAL ENTERPRISES LTD. - 500302 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Conference Call with Investors/ Analysts under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 PIRAMAL ENTERPRISES LTD. - 500302 - Announcement under Regulation 30 (LODR)-Meeting Updates
Regulations 30 and 51 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations') Outcome of Committee meeting Issuance of Secured, Rated, Listed, Redeemable, Principal Protected, Market Linked Non-Convertible Debentures up to Rs. 50 crores along with an option to retain oversubscription of up to Rs. 550 crores aggregating up to Rs. 600 crores on private placement basis